Liver disease accounts for approximately 2 million deaths per year worldwide, 1 million due
to complications of cirrhosis and 1 million due to viral hepatitis and hepatocellular …

Conclusions HBsAg‐positive patients with HCC are at high or intermediate risk of HBV
reactivation depending on the type of HCC therapy. Nucleos (t) ide analogue prophylaxis …

Background & Aims Functional cure, defined based on hepatitis B surface antigen (HBsAg)
loss, is rare during nucleos (t) ide analogue (NA) therapy and guidelines on finite NA …

Fructose intake is known to induce obesity, insulin resistance, metabolic syndrome, and
nonalcoholic fatty liver disease (NAFLD). We aimed to evaluate the effects of fructose …

Objective Although most patients with chronic hepatitis B (CHB) reach effective virological
suppression with long-term nucleos (t) ide analogues (NA) therapy, some might not need to …

HBsAg seroclearance occurs rarely in the natural history of chronic hepatitis B (CHB)
infection and is associated with improved clinical outcomes. Many factors are associated …

The number of effective systemic therapies for the treatment of advanced hepatocellular
carcinoma (HCC) is rapidly increasing, and the advent of immunotherapy has changed the …

Objective The use of tenofovir (TDF) and entecavir (ETV) in patients with chronic hepatitis B
(CHB) has led to a decrease in the incidence of hepatocellular carcinoma (HCC) and liver …

Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently,
two types of treatment, interferons (IFNs) and nucleos (t) ide analogues (NAs), have been …

Background & Aims A recent study in Asian patients with chronic hepatitis B (CHB) reported
that the incidence of hepatocellular carcinoma (HCC) was lower in patients treated with …